Early Detection of Cardiac Damage With CMR in Women With Breast Cancer

Radboud University Medical Center55 enrolled

Overview

With this study the investigators will assess early cardiac damage by means of Global Longitudinal Strain (GLS) in newly diagnosed breast cancer (BC) patients treated with anthracycline-based chemotherapy, and to investigate whether myocardial damage as measured with T1 / T2 Cardiovascular Magnetic Resonance (CMR) mapping and plasma hs-Troponin T is related to changes in GLS.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Cardiotoxicity Breast Cancer Chemotherapy Induced Systolic Dysfunction

Interventions

CMRDIAGNOSTIC_TEST

GLS measurement with CMR

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Female * Age ≥ 18 years * A diagnosis of primary breast cancer * Starting (neo-) adjuvant chemotherapy treatment within 2 months after screening * Cardiotoxicity risk score of intermediate, high or very high risk Exclusion Criteria: * Previous radiotherapy or systemic cancer treatment * Cancer metastasis * Life expectancy of less than 6 months * History of myocardial infarction or heart failure * Known contra-indications for CMR * Refusal or inability to provide informed consent

Locations (1)

Radboud University Medical Center

Nijmegen, Netherlands

RECRUITING

Outcomes

Primary Outcomes

Global Longitudinal Strain (GLS) change after chemotherapy compared to baseline

A relative reduction in Global Longitudinal Strain (GLS) assessed with CMR

Time frame: Baseline and 2 weeks after the last chemotherapy cycle

Central Contacts

Yvonne Koop, MSc

CONTACT

+31 24-3616785 Yvonne.Koop@radboudumc.nl

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.